Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro

Huang, Bing‐Shen; Huang, Shih‐Chiang; Chen, Fang-Hsin; Chang, Yu Han; Mei, Hsiu-Fu; Huang, Hsuan-Li; Chen, Wan‐Yu; Pang, Jong‐Hwei S.

doi:10.1016/j.lfs.2022.121072

Cited by 16 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that BPC 157, based primarily on animal model data, can act as a novel agent in the improvement of the clinical management of COVID-19 [ 167 ]. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro [ 65 ]. Similar effects and roles have also been noted in other species (i.e., birds [ 168 ], and insects, such as honeybees [ 169 , 170 ]).…”

Section: Discussionmentioning

confidence: 99%

“…Also, as mentioned above, BPC 157’s healing effect has been found to act as a membrane stabilizer (counteracting leaky gut syndrome) [ 10 ] and a free radical scavenger [ 10 , 11 , 55 , 66 , 75 , 76 , 79 , 80 , 89 , 90 , 91 ]. These effects have been recently associated with several molecular pathways [ 10 , 11 , 20 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ], in particular with the increased expression and internalization of VEGFR2, and the activation of the VEGFR2-Akt-eNOS signaling pathway [ 60 , 61 ], interacting particularly with the NO [ 49 ] and prostaglandins systems [ 50 ].…”

Section: Muscle Healingmentioning

confidence: 99%

“…Therefore, BPC 157 has a particular therapeutic effectiveness, including via a therapeutic per-oral regimen, and pleiotropic beneficial effects in terms of cytoprotection [ 3 , 4 , 32 , 33 , 34 ]. Furthermore, BPC 157 might particularly interact with many essential systems, i.e., the nitric oxide (NO)- [ 49 ], prostaglandins- [ 50 ], dopamine- [ 26 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ], and serotonin- [ 24 , 25 ] systems, known to be essential for both cytoprotection and muscle function integrity, and might interact with many molecular pathways [ 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ]. Illustratively, this might be the for the control of the vasomotor tone and the activation of the Src-Caveolin-1-eNOS pathway [ 60 , 61 ].…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, BPC 157 promoted the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway [ 58 , 59 ]. Likewise, other studies (muscle ischemia [ 60 , 61 ], muscle cachexia [ 10 ]) have indicated that particular molecular pathways involvement in the BPC 157 therapy muscle effect [ 10 , 11 , 20 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

et al. 2022

View full text Add to dashboard Cite

First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury. As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability to organize simultaneous healing of different tissues of and full recovery of the myotendinous junction might represent the particular muscle therapy against distinctive etiopathology muscle disabilities and weakness. In this, BPC 157 therapy might recover many of muscle disabilities (i.e., succinylcholine, vascular occlusion, spinal cord compression, stroke, traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome and NO-system blockade and tumor-cachexia). These might provide practical realization of the multimodal muscle-axis impact able to react depending on the condition and the given agent(s) and the symptoms distinctively related to the prime injurious cause symptoms in the wide healing concept, the concept of cytoprotection, in particular. Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (µg-ng regimens) and ways of application).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Muscle Healingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, BPC 157 acts as a membrane stabilizer (counteracting leaky gut) [ 10 ] and a free radical scavenger, particularly in vascular studies [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. Finally, these effects are also associated with several other molecular pathways [ 10 , 11 , 12 , 32 , 52 , 53 , 54 , 55 , 56 , 57 ].…”

Section: Discussionmentioning

confidence: 99%

Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157

et al. 2022

View full text Add to dashboard Cite

Recently, it was found that when confronted with major vessel occlusion and vascular failure, stable gastric pentadecapeptide BPC 157 therapy might rapidly functionally improve minor vessels to take over the function of disabled major vessels, reorganize blood flow, and compensate failed vessel function. We focused on the BPC 157 therapy effect obtained by giving 10 ng/kg ip to rats 5 min before sacrifice on the rat thoracic aorta, which we assessed with Fourier transform infrared spectroscopy (FTIR) 90 min thereafter. We applied a principal component analysis (PCA). The PCA model showed, with a clear distinction being mostly due to the PC1 score, differences between the spectra of BPC 157- and saline-treated rats. The comparison of the averaged spectra of these two groups with their differential spectrum and PC loadings allowed us to identify the parts of the FTIR spectra that contributed the most to the spectral separation of the two observed groups. The PC1 loadings and the differential spectrum showed that the main bands affecting the separation were the amid I band around 1650 cm−1, the amid II band around 1540 cm−1, and the vibrational band around 1744 cm−1. Fitting the spectral range between 1450 and 1800 cm−1 showed changes in protein conformation and confirmed the appearance of the vibrational band at 1744 cm−1. Controls had a substantially more intense vibrational band at 1744 cm−1. These spectral results showed the cells from saline-treated (control) rats to be in the early stage of cell death, while the samples from BPC 157-rats were protected. Thus, BPC 157 therapy changed the lipid contents and protein secondary structure conformation, with a rapid effect on vessels, within a short time upon application.

show abstract